Skip to main content

Table 3 ALK inhibitors in clinical use and development

From: Novel ALK inhibitors in clinical use and development

Drug Phase Tumors Common toxicities Reference
Crizotinib III NSCLC Visual disturbance, nausea, vomiting, constipation, edema [68-71]
Alectinib II/III NSCLC, ALCL, neuroblastoma Neutropenia, elevated CPK [79-82]
Ceritinib II/III NSCLC Diarrhea, elevated transaminases [86-91]
AP-26113 I/II NSCLC Nausea, fatigue, diarrhea [92-94]
ASP-3026 IB NSCLC Nausea, vomiting, constipation, abdominal pain [95,96]
X-376 Preclinical NSCLC, ALCL, neuroblastoma cell lines N/A [98]
X-396 Preclinical NSCLC, ALCL, neuroblastoma cell lines N/A [98]
TSR-011 I/II NSCLC, pancreatic, ovarian, and salivary gland cancers Dysaesthesia, QTc prolongation [99]
CEP-37440 I NSCLC, SCCHN, colorectal, pancreatic, prostate, and breast cancers Nausea, vomiting, diarrhea headaches [100]
NMS-E628 I/II advanced solid tumors N/A [102]
PF-06463922 I/IIA NSCLC N/A [103]
  1. ALCL-anaplastic large cell lymphoma; CPK-creatine phosphokinase; N/A-not available; NSCLC-non-small cell lung cancer; SCCHN-squamous cell cancer of head and neck.